Ezra M. Greenspan, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
Ninety-eight patients with multifocal metastatic breast carcinoma were treated with simultaneous combinations of thio-triethylenephosphoramide (TEPA) plus methotrexate (TP + MTX), cyclophosphamide (Cytoxan®) (Cyt) plus 5 fluorouracil (FU), TP + MTX + FU, or Cyt + MTX + FU. Maintenance alkylating agent (Alk) therapy (TP or Cyt) and intermittent courses of metabolic inhibitors (MTX or 5 FU) were given for 1 to 2 years. Central nervous system (CNS), hepatic, and diffuse preterminal disseminated metastases were also treated with moderate prednisone dosage. Hematostimulative supportive therapy included aqueous crystalline testosterone to masculinization, and monthly vitamin B12.
In a first group of 40 androgen-resistant
Greenspan EM. Five Year Study of Simultaneous Antimetabolites and Alkylating Agents in the Chemotherapy of Advanced Breast Carcinoma.. Ann Intern Med. ;62:1093. doi: 10.7326/0003-4819-62-5-1093_1
Download citation file:
Published: Ann Intern Med. 1965;62(5):1093.
Breast Cancer, Hematology/Oncology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use